The biggest challenge in moving to value-based care is the mindset of providers accustomed to volume-based care, as they must work with payers to change the systems, said Susan Dentzer, president and CEO of The Network for Excellence in Health Innovation.
The biggest challenge in moving to value-based care is the mindset of providers accustomed to volume-based care, as they must work with payers to change the systems, said Susan Dentzer, president and CEO of The Network for Excellence in Health Innovation.
Transcript (slightly modified)
What are the biggest challenges still facing healthcare as it moves to value-based care?
Number one, inertia. Systems are so embedded in the volume model, many of them. They really cannot see a path forward in the value model. Particularly if it means doing lots of things differently. If it means a conceptual mind shift that, my hospital is better off empty rather than full. The physicians and the other people in the workforce who I once needed in certain numbers that I thought were predictable, now I don’t really know what my workforce should look like. And I need to innovate around my workforce, maybe I need fewer specialists, and I need more community health workers and peer counselors. Particularly at large academic centers, where you have people with appointments and a strong institutional basis that this is the way we run things, it’s very, very hard to change. So I think that first and foremost is probably the biggest obstacle.
And then, you can’t just want to do this change as a provider, you’ve got to have the payers who are willing to engage with you. So is there a meeting of minds between payers and providers to move to value together, and work out the kinks together, because as we hear over and over again, there are lots of kinks along the way.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Managed Care Reflections: A Q&A With Dora Hughes, MD, MPH
September 4th 2025To mark the 30th anniversary of The American Journal of Managed Care, each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The September issue features a conversation with Dora Hughes, MD, MPH, chief medical officer and director of the Center for Clinical Standards and Quality at CMS.
Read More